What is Wolverine Stack researched for?

Wolverine Stack is a nickname for using BPC-157 together with TB-500. The source frames it around injury recovery, tendon and soft-tissue repair, inflammation, healing optimization, and joint repair, but it also states that the combination has not been tested in human clinical trials and that the support is mainly from animal studies of the separate components.

Is Wolverine Stack FDA approved?

No. The source states that Wolverine Stack is not FDA approved and describes the current status as preclinical research involving the components.

What side effects are reported?

The source lists injection site reactions, rare mild headache, fatigue during early use, and rare nausea. It does not provide controlled human safety rates for the BPC-157/TB-500 combination.

What typical dose is reported?

The source reports a community dose of 250-500 mcg of each peptide daily, once or twice daily, by subcutaneous injection. This is community-reported information and should not be treated as an evidence-based dosing recommendation.

Peptide Blend Preclinical - animal studies only

Wolverine Stack

Also known as: Wolverine Blend, BPC-157/TB-500 Stack, Healing Stack

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

BPC-157 and TB-500 blend discussed for repair-focused preclinical research

Status

Preclinical

Evidence level: animal studies

Typical dose

250–500mcg

Subcutaneous injection

Researched for

Injury recovery, healing optimization, joint repair

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

Preclinical - Promising animal research, limited human data

Use the tools

In plain language

Combination entry for BPC-157 and TB-500, commonly referred to as Wolverine Stack.
Source status is research for the components, with animal-study evidence emphasized.
Reported community dose is 250-500 mcg of each daily by injection.
Researched topics include injury recovery, healing optimization, and joint repair.
The source states the combination lacks human clinical trial evidence and is not FDA approved.

How it's thought to work

Wolverine Stack is presented as a two-component repair-focused blend rather than a single molecule. The source attributes BPC-157 activity to findings involving and growth-factor or nitric-oxide signaling in damaged tissue. TB-500 is described through its relationship to the actin-binding region of thymosin beta-4, with proposed effects on cell migration, actin regulation, and recruitment of cells involved in repair. The source explicitly limits these ideas to animal, cell, or other preclinical evidence rather than confirmed human effects for the stack.

What the research shows

Where the research stands

The source states that Wolverine Stack itself has no human evidence as a combination. It also reports no completed phase 2 or phase 3 tissue-repair trials for BPC-157 or TB-500 individually. The cited evidence base is described as mostly rodent, animal, and cell-model research: BPC-157 is associated in those models with tendon, ligament, muscle, and gut-healing findings, while TB-500 or thymosin beta-4 biology is associated with wound-healing and cell-migration models. The source notes that full thymosin beta-4 has reached human trials in areas such as pressure ulcers and dry eye, but distinguishes that from the TB-500 fragment used in stack discussions.

What it shows

✓ Animal studies

Promising animal research, limited human data

△ Limitations

Animal study doses may not translate directly to humans.

Bottom line: Preclinical Research (Components) Not FDA Approved

Typical dosing

CommunityCommunity dataset

250–500 mcg

of each peptide daily

250 mcgfull range seen500 mcg

Community-reported dosing only; the source does not establish this as a clinically validated regimen. · Subcutaneous injection

Research dosing

Animal studies onlyAnimal studies only - may not translate to humans

Doses observed in studies

BPC-157 10mg + TB-500 10mg per vial

Animal study doses may not translate directly to humans.

Duration: 4-12 weeks depending on injury
Administration: Subcutaneous injection

Timing & administration

Best time to take

Morning or post-workout

Once or twice daily

Food recommendation

With or without food

Why this timing?

The source links timing to healing-cycle alignment and optional local administration logic, but does not provide human trial evidence validating a timing advantage.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Injection site reactions
Mild headache
Fatigue during initial use
Nausea

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

The proposed rationale is that the two components may affect different repair biology. BPC-157 is described as influencing blood-vessel formation and growth-factor or nitric-oxide pathways in rodent tissue-injury models. TB-500 is described as related to thymosin beta-4 actin biology, cell movement, and repair-cell recruitment. The source presents this as a preclinical hypothesis, not validated human pharmacology.

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on Wolverine Stack

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

Wolverine Stack

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows

Typical dosing

Research dosing

Timing & administrationTiming & administration

Possible side effectsPossible side effects

SourcesSources

Frequently asked questionsFrequently asked questions